This study focuses on Alpha-1 Antitrypsin Deficiency, a genetic condition that can cause lung problems. The study will test a medication called Kamada-AAT for Inhalation, which is an inhaled solution containing human alpha1-proteinase inhibitor. The treatment will be delivered using a special device called an eFlow Nebuliser System.
The purpose of this research is to determine if inhaling 80 mg of Kamada-AAT daily can help people with moderate to severe breathing difficulties caused by Alpha-1 Antitrypsin Deficiency. The study will compare the medication to placebo to see how well it works in improving lung function. Participants will use either the study medication or placebo through a nebulizer device for two years.
During the study, participants will have their lung function tested regularly using various breathing tests. The main focus will be on measuring how well the lungs work after using an inhaler. After the initial two-year period, participants will have the opportunity to continue treatment for an additional two years where all participants will receive the active medication.



Belgium
Finland
Ireland
Sweden
The Netherlands